Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Chronic lymphocytic leukemia
Phase 2 nemtabrutinib reversible non-covalent BTK inhibitor + venetoclax BCL-2 inhibitor in frontline CLL/SLL.
This Phase 2, single-arm frontline study evaluates an all-oral combination of nemtabrutinib (MK-1026)—a reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that can inhibit wild-type BTK and some BTK…
NCT07557056 Exploratory - New trial
Multiple myeloma
Phase 2 DREAMM-15: belantamab mafodotin BCMA-targeting MMAF ADC in RRMM combinations
GlaxoSmithKline’s DREAMM-15 is a Phase 2, multicenter, open-label, non-randomized study testing extended-interval dosing of belantamab mafodotin (Blenrep)—a BCMA-directed antibody–drug conjugate delivering MMAF, a…
NCT07227311 Exploratory - New trial Spotlight
Head and neck cancer
Phase 1/2 ficerafusp alfa EGFR×TGF-β bifunctional antibody with pembrolizumab + neoadjuvant SBRT
Washington University School of Medicine is running this open-label, sequential-assignment Phase 1/2 trial testing whether short-course neoadjuvant SBRT plus pembrolizumab (Merck’s anti–PD-1 antibody) can be safely…
NCT07552558 Exploratory - New trial
Head and neck cancer
Phase 2 CADI-05 poly‑TLR agonist (heat‑killed Mycobacterium indicus pranii immunotherapy) + pembrolizumab PD‑1 inhibitor in resectable LA‑HNSCC.
This single-site, open-label neoadjuvant study at Fox Chase Cancer Center tests whether adding CADI-05—an intradermal innate-immune activator described by NCI as a poly‑TLR agonist, polyantigenic vaccine made from…
NCT07455032 Exploratory - New trial
Head and neck cancer
Pilot randomized trial of Avive+ amnion soft‑tissue barrier to reduce radial nerve morbidity
This University of Alabama at Birmingham (UAB) single-blind, randomized, parallel-group pilot study tests whether adding Avive+ Soft Tissue Matrix to the radial forearm free flap (RFFF) donor site can reduce…
NCT07558096 Exploratory - New trial Spotlight
Colorectal cancer
Phase 1 CEA-PRIT 2.0 pretargeted alpha therapy targeting CEACAM5 (CEA)
This first-in-human, open-label Phase 1 study from Roche/Genentech evaluates CEA-PRIT 2.0, a multi-step “pretargeted” radioimmunotherapy designed to deliver the alpha-emitter lead-212 to CEACAM5 (CEA)–expressing…
NCT07416552 First-in-human - New trial
Other blood cancers and transplant
Phase 2 treosulfan/fludarabine conditioning plus PTCy alkylator-based GVHD prophylaxis in allo-HSCT.
This Phase 2, single-center study at the Masonic Cancer Center (University of Minnesota) evaluates a reduced-intensity allogeneic hematopoietic stem cell transplant approach for hematologic diseases, including AML…
NCT07493538 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 D3S-003 dual-state KRAS G12D inhibitor (targets GDP- and GTP-bound KRAS)
This first-in-human, open-label Phase 1 study evaluates D3S-003 monotherapy in adults with advanced/metastatic solid tumors harboring a KRAS p.G12D mutation, focusing on safety, tolerability,…
NCT07456046 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 ML261 DLL3-targeted CAR-T with CARD11–PIK3R3 “armoring” fusion in R/R SCLC/NECs.
This first-in-human, open-label Phase 1 trial (SPECTRAL-1) evaluates ML261, an autologous anti-DLL3 chimeric antigen receptor (CAR) T-cell therapy that also expresses a CARD11–PIK3R3 fusion transgene intended to…
NCT07488923 First-in-human - New trial
Multiple solid tumors
Phase 1 PF-08046033 GPNMB-targeted antibody-drug conjugate delivers auristatin tubulin payload.
This first-in-human, open-label Phase 1 trial from Pfizer tests PF-08046033 as IV monotherapy in adults with metastatic/unresectable, progressive solid tumors, starting with dose escalation (multiple ascending dose…
NCT07519655 First-in-human - New trial
Multiple solid tumors
Phase 1/1b RGT-490 mutant-selective PI3Kα inhibitor in PIK3CA-mutant solid tumors.
This first-in-human, open-label Phase 1/1b study tests RGT-490, an oral small molecule designed as a mutant-selective PI3Kα (PIK3CA) inhibitor, aiming to suppress oncogenic PI3K pathway signaling while potentially…
NCT07524322 First-in-human - New trial
Multiple solid tumors
Phase 1 KIVU-107 PTK7-targeted antibody-drug conjugate in advanced solid tumors
This first-in-human, open-label Phase 1 study (KIVU-107-01) from Kivu Bioscience evaluates KIVU-107, a PTK7-directed antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload to PTK7-expressing tumor…
NCT07229313 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b BG-C0979 ADAM9-targeted ADC with Topo1 inhibitor payload ± tislelizumab
This first-in-human, multicenter, open-label Phase 1a/1b study tests BG-C0979, an ADAM9-targeted antibody-drug conjugate (ADC) delivering a DNA topoisomerase I (Topo1) inhibitor payload, sponsored by BeOne Medicines…
NCT07414836 First-in-human - New trial
Multiple solid tumors
Phase 1b/2 ASP546C CLDN18.2-targeted ADC with topoisomerase I inhibitor payload
Astellas Pharma Global Development is running this Phase 1b/2, open-label, multicohort study to define a tolerable, active dose and characterize safety/PK plus preliminary efficacy of ASP546C. ASP546C is an…
NCT07488676 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Taletrectinib (CNS-penetrant ROS1 TKI) posts ~90% ORR and ~46-mo mPFS in ROS1+ NSCLC first-line
Taletrectinib is an oral, next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) with CNS activity; this pooled update of the single-arm Phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials…
NCT04395677 - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 100% MRD(10⁻⁶) negativity by 2 months in high-risk SMM
Ciltacabtagene autoleucel (cilta-cel) is a BCMA-targeted autologous CAR-T; in the CAR-PRISM Phase 2 trial (NCT05767359), HR-SMM patients received a single cilta-cel infusion (0.3–0.5×10⁶ or >0.5×10⁶ viable CAR+ T…
NCT05767359 - Trial result
Colorectal cancer
BXQ-350 (Saposin C nanovesicle; sphingolipid “homeostasis” modulator) + mFOLFOX7/bevacizumab posts 61% ORR in 1L mCRC
BXQ-350 is a Saposin C nanovesicle designed to allosterically activate sphingolipid metabolism—reported here to lower GM3/GluCer/S1P and raise ceramides—combined with first-line mFOLFOX7 plus bevacizumab in a Phase…
NCT05322590 - Trial result
Colorectal cancer
Perioperative propranolol (β-blocker) + etodolac (COX-2 inhibitor) shows manageable bradycardia and exploratory DFS signal in CRC
Perioperative propranolol (non-selective β-adrenergic blocker; slow-release, titrated from 20mg BID pre-op to 80mg BID on surgery day) plus etodolac (semi-selective COX-2 inhibitor; 400mg BID) was evaluated across…
NCT00502684 - Trial result
Stomach and esophageal cancer
T-DXd (HER2 ADC) + rilvegostomig (PD-1×TIGIT) + fluoropyrimidine delivers 70% ORR as 1L HER2+ gastroesophageal triplet
Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (topoisomerase I payload) and rilvegostomig is an Fc-reduced PD-1×TIGIT bispecific antibody; DESTINY-Gastric03 Part 4 arm A (NCT04379596)…
NCT04379596 - Trial result
Melanoma
Sotigalimab (intratumoral CD40 agonist) + pembrolizumab delivers 50% ORR and abscopal activity in metastatic melanoma
Sotigalimab (APX005M) is an intratumoral CD40 agonistic antibody designed to activate antigen-presenting cells (APCs); here it was combined with systemic pembrolizumab (anti–PD-1) in an ICB-naïve metastatic melanoma…
NCT02706353 - Trial result Spotlight
Prostate cancer
Niraparib (PARP inhibitor) + abiraterone (CYP17 inhibitor) drives 38.6-mo rPFS in BRCA2+ Asian 1L mCRPC
Niraparib is an oral PARP inhibitor that exploits homologous recombination repair deficiency; here it was combined with abiraterone acetate + prednisone (AAP), an androgen biosynthesis (CYP17) inhibitor backbone, in…
NCT03748641 - Trial result
Prostate cancer
Cabazitaxel (microtubule-inhibitor taxane)–based “cabascore” stratifies mCRPC survival and predicts benefit vs 2nd ARPI
CABASTY post hoc (n=194) derived a 6-variable Cox-model “cabascore” (ECOG PS 0 vs 1–2, <2 vs ≥2 metastatic sites, PSA, LDH, ALP, hemoglobin) and split patients on cabazitaxel into favorable/intermediate/poor groups…
- Trial result
Brain and CNS tumors
Bortezomib (26S proteasome/NF-κB inhibition) + sequential temozolomide extends OS to 18.8 months in recurrent uMGMT GBM
Sequential bortezomib (BTZ), an IV 26S proteasome inhibitor that can suppress NF-κB signaling and deplete MGMT protein, was given 48 hours before temozolomide (TMZ) in the BORTEM-17 Phase IB/II recurrent glioblastoma…
NCT03643549 - Trial result
Chronic myeloid leukemia
Asciminib (STAMP/ABL myristoyl-pocket inhibitor) posts ~39% Week-48 MMR in ≥3L CML-CP optimization study
Asciminib (Scemblix) is a first-in-class STAMP inhibitor that allosterically targets the ABL1 myristoyl pocket (vs ATP-competitive TKIs), evaluated in the non-comparative Phase 3b ASC4OPT study (NCT04948333) in…
NCT04948333 - Trial result
Liver and bile duct cancer
TheraSphere (Y-90 glass microspheres) SIRT delivers 21.8-mo real-world OS in HCC, with a clear ≥400Gy dose–survival signal
Yttrium-90 (Y-90) glass microsphere selective internal radiation therapy (SIRT; TheraSphere™) is a catheter-delivered liver-directed radiotherapy that treats HCC by delivering high beta radiation doses to tumor while…
- Trial result
Acute lymphoblastic leukemia
Short-course blinatumomab (CD19×CD3 BiTE) clears MRD in B-ALL and gets 90% to transplant in a resource-limited program
Blinatumomab is a CD19×CD3 bispecific T-cell engager (BiTE) given here as a deliberately shortened “MRD-eradication” bridge to allogeneic HCT in CD19+ B-ALL patients in CR with detectable MRD and ≤5% blasts (n=20;…
- New trial Spotlight
Brain and CNS tumors
Phase 1 EGFR/IL13Rα2 pool-CAR T cells target EGFR + IL13Rα2 in HGG
City of Hope Medical Center is running a Phase 1, first-in-human, open-label, dose-finding study of autologous “pool-CAR” T cells engineered to recognize EGFR and IL13Rα2 on tumor cells (dual-antigen CAR T…
NCT07544992 First-in-human - New trial
Brain and CNS tumors
Phase 1b sitagliptin DPP-4 inhibitor + bevacizumab anti-VEGF mAb in recurrent grade 4 glioma
This Phase 1 trial tests repurposed sitagliptin (a small-molecule dipeptidyl peptidase-4 [DPP-4] inhibitor; Merck’s Januvia) combined with bevacizumab (a VEGF-A–neutralizing monoclonal antibody; Genentech/Roche’s…
NCT07541781 Exploratory - New trial
Brain and CNS tumors
Phase 1/2 mirdametinib MEK1/2 inhibitor tests MAPK-driven CNS tumors, perioperative glioma cohort
This Phase 1/2, multicenter, open-label Memorial Sloan Kettering (MSK) study evaluates mirdametinib, an oral small-molecule inhibitor of MEK1 and MEK2 in the MAPK pathway, in two biologically selected CNS tumor…
NCT07539441 Exploratory - New trial
Pancreatic cancer
Phase 1b pitavastatin HMG‑CoA reductase inhibitor plus gemcitabine/nab‑paclitaxel in uPDAC.
This Phase 1b, open-label, randomized maintenance study at University of California, Irvine tests whether adding pitavastatin (a small‑molecule HMG‑CoA reductase inhibitor that suppresses the mevalonate/cholesterol…
NCT07549958 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.